

## Clinical Policy: Fecal Incontinence Treatments

Reference Number: WNC.CP.125

Last Review Date:

Coding Implications

Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

**Note:** When state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

### Description

Fecal incontinence is generally defined as the uncontrolled passage of feces over at least three month's duration in an individual who had previously achieved control.<sup>1</sup> It has substantial social and economic impact and significantly impairs quality of life.<sup>2</sup> The choice of therapy depends upon the etiology of incontinence, the anatomy of the sphincters, and the effect of incontinence has on the quality of life.

### Policy/Criteria

- I. It is the policy of WellCare of North Carolina® that procedures to treat fecal incontinence are medically necessary when meeting the **BOTH** of the following:
  - A. Severe, chronic fecal incontinence (defined as greater than two incontinent episodes on average per week and duration of incontinence greater than six months) that has not responded adequately to conservative treatments (e.g., pharmacotherapy, dietary management, strengthening exercises), in a member that has previously achieved bowel control;
  - B. Requested procedure meets **one** of the following:
    1. Sacral nerve stimulation (sacral neuromodulation) for a weak but structurally intact anal sphincter when **all** of the following criteria is met:
      - a. A test of percutaneous stimulation was effective, defined as at least 50% sustained (more than one week) improvement in symptoms;
      - b. Condition is not related to anorectal malformation (e.g., congenital anorectal malformation, defects of the external anal sphincter over 60 degrees, visible sequelae of pelvic radiation, active anal abscesses and fistulae) and/or chronic inflammatory bowel disease;
      - c. Incontinence is not related to another neurologic condition such as peripheral neuropathy or complete spinal cord injury;
      - d. Member demonstrates the ability to operate the device or has a supportive caregiver who could otherwise provide assistance
      - e. Has none of the following contraindications:
        - i. Mechanical outlet obstruction;
        - ii. Diathermy use (shortwave, microwave, ultrasound);
    2. Artificial bowel sphincter (Acticon Neosphincter) when **all** of the following criteria is met:
      - a. Age ≥ 18 years;

- b. Failure of, or not a candidate for, medical interventions or surgical sphincter repair;
    - c. Incontinence is not complicated by an irreversibly obstructed proximal segment of bowel;
  - 3. Colostomy, as last resort, when all other treatments have failed or are contraindicated.
- II. It is the policy of WellCare of North Carolina<sup>®</sup> that the following procedures have not been proven effective for the treatment of fecal incontinence:
  - A. Transanal radiofrequency therapy (Secca procedure);
  - B. Injectable bulking agents [e.g., dextranomer/hyaluronic acid (Solesta)];
  - C. Anal electrical stimulation;
  - D. Posterior tibial nerve stimulation;
  - E. Vaginal bowel control (e.g., Eclipse system);
  - F. Sacral nerve stimulation for the treatment of chronic constipation or chronic pelvic pain.

### **Background**

Treatment of fecal incontinence is challenging. The goal of treatment is to restore continence and to improve the quality of life. Dietary and medical management are initially recommended for patients with fecal incontinence. If fecal incontinence is a result of or in conjunction with anatomic defects (e.g., rectovaginal fistula, rectal or hemorrhoidal prolapse etc.), the defects should be corrected first as this often improves or eliminates the incontinence.<sup>1</sup> Although most current interventions show modest improvements, there is limited evidence to support any treatments for fecal incontinence past 3 to 6 months.<sup>3,4</sup>

**Sacral neuromodulation** is thought to modulate rectal sensation by activating or deactivating chemical mediating receptors, stimulating the afferent pathway, and changing brain activity relevant to the continence. Sacral neuromodulation has consistently resulted in a reduction in frequency of fecal incontinence episodes and may be considered for incontinent patients with and without sphincter defects. Sphincter repair (sphincteroplasty) can be a treatment option for symptomatic patients with a defined defect of the external anal sphincter. Implantation of an artificial bowel sphincter remains an effective tool for select patients with severe fecal incontinence; however, its use is limited by complications including explanation in up to one-third of patients.<sup>1,2,5</sup>

**Injectable bulking agents** [e.g., dextranomer/hyaluronic acid (Solesta)] have been investigated for the treatment of fecal incontinence. However, evidence in the peer review literature evaluating this treatment is limited. There is a paucity of randomized, controlled trials and studies are limited by their small study sizes.<sup>2</sup> A prospective multicenter trial of 136 patients with fecal incontinence who received non-animal stabilized hyaluronic acid/dextranomer (NASHA Dx) bulking agent reported it provided a significant improvement of fecal incontinence symptoms in a majority of patients and this effect was stable during the course of the follow-up

## CLINICAL POLICY WNC.CP.125

### FECAL INCONTINENCE TREATMENTS

and was maintained for 3 years.<sup>3</sup> Long-term data is lacking, however, regarding the durability of this treatment.<sup>6</sup>

**Transanal radiofrequency therapy** (e.g., Secca procedure) is another procedure proposed for the treatment of fecal incontinence). This procedure uses thermo-controlled delivery of radiofrequency energy to the anal canal. The reported evidence is relatively sparse and has relevant limitations. Most studies have been small single-center series with short to mid-term follow-up.<sup>7,8</sup>

**The Eclipse System** (Pelvalon Inc) is a nonsurgical vaginal bowel-control system for the treatment of fecal incontinence in women 18 to 75 years old who have had four or more FI (fecal incontinence) episodes in a two-week period. The device includes an inflatable balloon, which is placed in the vagina. Upon inflation, the balloon exerts pressure through the vaginal wall onto the rectal area, thereby reducing the number of FI episodes. The device is initially fitted and inflated by a clinician (with the use of a pump) and after proper fitting, the patient can inflate and deflate the device at home as needed. The device was granted FDA approval through the de novo classification process based on non-clinical testing as well as a clinical trial of 61 women with Fecal Incontinence treated with the device. The trial showed that after one month almost 80 percent of women in the study experienced a 50 percent decrease in the number of fecal incontinence episodes while using the device, as compared to baseline. Studies to date are limited by size and lack of long term evidence.<sup>9,10</sup>

#### **American Society of Colon and Rectal Surgeons (ASCRS)**

In their most recent 2023 guidelines on the treatment of fecal incontinence, the ASCRS assigns conditional recommendations for sacral neuromodulation and sphincteroplasty based upon low quality of evidence. The ASCRS reports that injection of biocompatible bulking agents into the anal canal may help to decrease episodes of passive fecal incontinence. However, the ASCRS notes that “given the limited improvement over placebo, diminishing long-term results, and cost, injectable bulking agents are not considered first-line treatment for fecal incontinence.”<sup>1</sup> The ASCRS guideline states the application of temperature-controlled radiofrequency energy to the sphincter complex is not recommended for the treatment fecal incontinence. Per the ASCRS, “the evidence supporting this approach is relatively sparse and has relevant limitations, additionally, no new studies evaluating this modality have been published since 2014.”<sup>1</sup>

#### **American College of Gastroenterology (ACG)**

Regarding minimally invasive procedures for the treatment of fecal incontinence, the ACG concluded that minimally invasive procedures such as injectable anal bulking agents may have a role in patients with fecal incontinence who do not respond to conservative therapy. However, they note this is a weak recommendation based on moderate quality of evidence. The ACG reported that there is insufficient evidence to recommend radiofrequency ablation treatment to the anal sphincter (SECCA) at this time.<sup>7</sup>

#### **National Institute for Health and Clinical Excellence**

An interventional procedure guidance on injectable bulking agents for fecal incontinence concluded the current evidence on the safety and efficacy of injectable bulking agents for fecal

# CLINICAL POLICY WNC.CP.125

## FECAL INCONTINENCE TREATMENTS



incontinence does not appear adequate for this procedure to be used without special arrangements for consent and for audit or research, which should take place in the context of a clinical trial or formal audit protocol that includes information on well-defined patient groups.<sup>6</sup>

### American College of Obstetricians and Gynecologists (ACOG)

A practice bulletin on fecal incontinence concluded that anal sphincter bulking agents may be effective in decreasing fecal incontinence episodes up to 6 months and can be considered as a short-term treatment option for fecal incontinence in women who have failed more conservative treatments. However, this was based on limited or inconsistent scientific evidence (Level B).<sup>3</sup>

### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2025, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT®* Codes	Description
44320	Colostomy or skin level cecostomy
46750	Sphincteroplasty, anal, for incontinence or prolapse; adult
46751	Sphincteroplasty, anal, for incontinence or prolapse; child
46760	Sphincteroplasty, anal, for incontinence, adult; muscle transplant
46761	Sphincteroplasty, anal, for incontinence, adult; levator muscle imbrication (Park posterior anal repair)
46999	Unlisted procedure, anus
64561	Percutaneous implantation of neurostimulator electrodes; sacral nerve (transforaminal placement) including image guidance, if performed
64581	Open implantation of neurostimulator electrodes; sacral nerve (transforaminal placement)
64585	Revision or removal of peripheral neurostimulator electrodes
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
64595	Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver
95970	Electronic analysis of implanted neurostimulator pulse generator/transmitter [e.g. contact group(s), interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal

**CLINICAL POLICY WNC.CP.125**  
**FECAL INCONTINENCE TREATMENTS**



<b>CPT®*</b> <b>Codes</b>	<b>Description</b>
	cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without programming
95971	Electronic analysis of implanted neurostimulator pulse generator /transmitter system [e.g. contact group(s), interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters] by physician or other qualified health care professional; with simple spinal cord or peripheral nerve (e.g., sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional
95972	Electronic analysis of implanted neurostimulator pulse generator /transmitter [e.g., contact group (s), interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters] by physician or other qualified health care professional; with complex spinal cord or peripheral nerve (e.g., sacral nerve) neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional

<b>HCPCS®*</b> <b>Codes</b>	<b>Description</b>
A4290	Sacral nerve stimulation test lead, each
A4335	Incontinence supply; miscellaneous
C1767	Generator, neurostimulator (implantable), non-rechargeable
C1778	Lead, neurostimulator (implantable)
E0745	Neuromuscular stimulator, electronic shock unit
L8680	Implantable neurostimulator electrode, each
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
L8682	Implantable neurostimulator radiofrequency receiver
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver
L8684	Radiofrequency transmitter (external) for use with implantable sacral root neurostimulator receiver for bowel and bladder management, replacement
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension
L8689	External recharging system for battery (internal) for use with implantable neurostimulator, replacement only

**CLINICAL POLICY WNC.CP.125**  
**FECAL INCONTINENCE TREATMENTS**



**CPT codes that do not support coverage criteria**

<b>CPT® Codes</b>	<b>Description</b>
64566	Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming

**HCPCS codes that do not support coverage criteria**

<b>HCPCS® Codes</b>	<b>Description</b>
L8605	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies

<b>Reviews, Revisions, and Approvals</b>	<b>Reviewed Date</b>	<b>Approval Date</b>
Original approval date	03/21	05/21
Updated criteria in Sections C.1.b, "b. Condition is not related to anorectal malformation (e.g., congenital anorectal malformation, defects of the external anal sphincter over 60 degrees, visible sequelae of pelvic radiation, active anal abscesses and fistulae) and/or chronic inflammatory bowel disease" and C.1.c. "c. Incontinence is not related to another neurologic condition such as peripheral neuropathy or complete spinal cord injury." Updated investigational verbiage in Section D. Reviewed CPT, HCPCS, and ICD-10-CM codes. Added HCPCS code that does not support medical necessity criteria. References reviewed and updated Annual review.	05/22	08/22
Section I.B. Verbiage updated, HCPCS H0012, H2011, H2012 modifier verbiage added, HCPCS H0014 H0020 H0035 H2011 H2022 2035 H2036 S9484 Descriptions updated, HCPCS H2012 Child and Adolescent Day Treatment AND H2033 Multisystemic Therapy ADDED. Under HCPCS, NOTES added: "components of service...", "telehealth claims: Modifier GT..." and "telehealth claims, usual place of service codes..."	08/22	08/22
NCHC verbiage removed from NC Guidance Verbiage.	04/23	04/23
Annual Review. Added CPT codes 46750 46751 46760 46761 95970 95971 95972, . Updated description for CPT codes 64590 (changed 'and' to 'or'). References reviewed and updated.	08/23	08/23
Annual review. Criteria I.A. Removed "≥ 4 years age" and added "in a member/enrollee that has previously achieved bowel control." Added Code CPT Code 64566 "Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming" to "codes that do not support coverage criteria." Removed ICD-10-CM Diagnosis codes from policy. Description and background section updated with no clinical significance. References reviewed and updated.	11/23	11/23



**CLINICAL POLICY WNC.CP.125**  
**FECAL INCONTINENCE TREATMENTS**



Reviews, Revisions, and Approvals	Reviewed Date	Approval Date
Annual review. Minor rewording in Description and in Background with no impact on criteria. References reviewed and updated.	11/24	11/24
Annual review. Added criteria I.B.1.d. Member/enrollee demonstrates the ability...and removed I.B.1.e.iii. Inadequate response to test stimulation...and I.B.3.d. Absence of any physical or mental illness... Removed previous criteria I.B.2. for sphincteroplasty. Reworded Criteria II with no impact on criteria. Added CPT 44320 and HCPCS C1767, C1778 to coding tables. References reviewed and updated. Under NC Guidance/Claims related information, updated state web address.		

**References**

1. Bordeianou LG, Thorsen AJ, Keller DS, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence. *Dis Colon Rectum*. 2023;66(5):647 to 661. doi:10.1097/DCR.0000000000002776
2. Lembo A.J., Spivak A.R. Fecal incontinence in adults: management. UpToDate. [www.uptodate.com](http://www.uptodate.com). Published November 10, 2023. Accessed April 2, 2025.
3. ACOG Practice Bulletin No. 210 : Fecal Incontinence [published correction appears in *Obstet Gynecol*. 2019 Nov;134(5):1121]. *Obstet Gynecol*. 2019;133(4):e260-e273. doi:10.1097/AOG.00000000000003187
4. Forte ML, Andrade KE, Butler M, et al. Treatments for Fecal Incontinence. Rockville (MD): Agency for Healthcare Research and Quality (US); March 2016.
5. Melenhorst J, Koch SM, van Gemert WG, Baeten CG. The artificial bowel sphincter for faecal incontinence: a single centre study. *Int J Colorectal Dis*. 2008;23(1):107-111. doi:10.1007/s00384-007-0357-0
6. National Institute for Health and Clinical Excellence. Injectable bulking agents for fecal incontinence. <https://www.nice.org.uk/guidance/ipg210/resources/injectable-bulking-agents-for-faecal-incontinence-pdf-1899865208328901> Published February 28, 2007 (updated January 16, 2012). Accessed April 1, 2025.
7. Wald A, Bharucha, AE, Limketkai B, et al. ACG Clinical Guidelines: Management of Benign Anorectal Disorders. *Am J Gastroenterol*. 2021;116(10):1987-2008. doi:10.14309/ajg.0000000000001507
8. Lam TJ, Visscher AP, Meurs-Szojda MM, Felt-Bersma RJ. Clinical response and sustainability of treatment with temperature-controlled radiofrequency energy (Secca) in patients with faecal incontinence: 3 years follow-up. *Int J Colorectal Dis*. 2014 Jun;29(6):755 to 61. doi: 10.1007/s00384-014-1882-2
9. van der Wilt AA, Giuliani G, Kubis C, et al. Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients with faecal incontinence. *Br J Surg*. 2017;104(9):1167 to 1176. doi:10.1002/bjs.10590
10. Varma MG, Matthews CA, Muir T, et al. Impact of a novel vaginal bowel control system on bowel function. *Dis Colon Rectum*. 2016;59(2):127-131. doi:10.1097/DCR.0000000000000517

11. La Torre F, de la Portilla F. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence. *Colorectal Dis.* 2013 May;15(5):569 to 74. doi: 10.1111/codi.12155
12. Franklin H, Barrett AC, Wolf R. Identifying factors associated with clinical success in patients treated with NASHA(®)/Dx injection for fecal incontinence. *Clin Exp Gastroenterol.* 2016 Mar 2;9:41 to 7. doi: 10.2147/CEG.S95238
13. Graf W, Mellgren A, Matzel KE, et al. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. *Lancet.* 2011;377(9770):997 to 1003. doi:10.1016/S0140-6736(10)62297-0
14. Frascio M, Stabilini C, Casaccia M, et al. Radiofrequency Procedure (SECCA®) for Fecal Incontinence: One-Year Experience. *Surg Technol Int.* 2017;30:97 to 101.
15. Visscher AP, Lam TJ, Meurs-Szojda MM, Felt-Bersma RJF. Temperature-Controlled Delivery of Radiofrequency Energy in Fecal Incontinence: A Randomized Sham-Controlled Clinical Trial. *Dis Colon Rectum.* 2017 Aug;60(8):860 to 865. doi:10.1097/DCR.0000000000000861
16. Al-Bayati I, Saadi M, Elhanafi S, McCallum RW. Effectiveness of Bulking Agent (Solesta) Therapy in Fecal Incontinence in Patients Refractory to Conventional Therapies. *Am J Med Sci.* 2017 Nov;354(5):476 to 479. doi:10.1016/j.amjms.2017.09.001
17. van der Wilt AA, Giuliani G, Kubis C, et al. Randomized clinical trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in patients with faecal incontinence. *Br J Surg.* 2017;104(9):1167 to 1176. doi:10.1002/bjs.10590
18. Mellgren A, Matzel KE, Pollack J, et al. Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence. *Neurogastroenterol Motil.* 2014;26(8):1087 to 1094. doi:10.1111/nmo.12360
19. Sanchez JE, Brenner DM, Franklin H, Yu J, Barrett AC, Paterson C. Validity of the  $\geq 50\%$  Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal Incontinence. *Clin Transl Gastroenterol.* 2015;6(1):e70. Published 2015 Jan 15. doi:10.1038/ctg.2014.20
20. Ruiz D, Pinto RA, Hull TL, Efron JE, Wexner SD. Does the radiofrequency procedure for fecal incontinence improve quality of life and incontinence at 1-year follow-up? *Dis Colon Rectum.* 2010 Jul;53(7):1041 to 6. doi: 10.1007/DCR.0b013e3181defff8
21. Local coverage article: billing and coding: sacral nerve stimulation for urinary and fecal incontinence (A53017). Centers for Medicare and Medicaid Services website. <http://www.cms.hhs.gov/mcd/search.asp>. Published October 1, 2015 (revised January 01, 2024). Accessed April 2, 2025.
22. Felt-Bersma RJ. Temperature-controlled radiofrequency energy in patients with anal incontinence: an interim analysis of worldwide data. *Gastroenterol Rep (Oxf).* 2014 May;2(2):121 to 5. doi: 10.1093/gastro/gou016
23. Local coverage determination: sacral nerve stimulation for the treatment of urinary and fecal incontinence (L39543). Centers for Medicare and Medicaid Services website. <http://www.cms.hhs.gov/mcd/search.asp>. Published November 05, 2023. Accessed April 2, 2025.
24. Goldman HB, Lloyd JC, Noblett KL, et al. International Continence Society best practice statement for use of sacral neuromodulation. *Neurourol Urodyn.* 2018;37(5):1823-1848. doi:10.1002/nau.23515



## CLINICAL POLICY WNC.CP.125

### FECAL INCONTINENCE TREATMENTS

25. Ellsworth PI. Sacral Nerve Stimulation. *Medscape*.  
<https://emedicine.medscape.com/article/2036909-overview>. Published September 20, 2023.  
Accessed April 1, 2025.
26. Feloney MP, Stauss K, Leslie SW. Sacral Neuromodulation. Treasure Island, FL: StatPearls Publishing; 2024. <https://www.ncbi.nlm.nih.gov/books/NBK567751/>. Accessed April 1, 2025.
27. Takahashi-Monroy T, Morales M, Garcia-Osogobio S, Valdovinos MA, Belmonte C, Barreto C, Zarate X, Bada O, Velasco L. SECCA procedure for the treatment of fecal incontinence: results of five-year follow-up. *Dis Colon Rectum*. 2008 Mar;51(3):355 to 9. doi: 10.1007/s10350-007-9169-0
28. AMS Acticon™ Neosphincter. [package insert]. Minnetonka, MN: American Medical Systems; 1999.
29. Gregorcyk SG. The current status of the Acticon Neosphincter. *Clin Colon Rectal Surg*. 2005;18(1):32-37. doi:10.1055/s-2005-864078

#### **North Carolina Guidance**

##### *Eligibility Requirements*

- a. An eligible beneficiary shall be enrolled in the NC Medicaid Program (Medicaid is NC Medicaid program, unless context clearly indicates otherwise);
- b. Provider(s) shall verify each Medicaid beneficiary's eligibility each time a service is rendered.
- c. The Medicaid beneficiary may have service restrictions due to their eligibility category that would make them ineligible for this service.

##### *EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age*

- a. 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]  
Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiary under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed practitioner).

This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his or her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary's physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary's right to a free choice of providers.

## CLINICAL POLICY WNC.CP.125

### FECAL INCONTINENCE TREATMENTS



EPSDT does not require the state Medicaid agency to provide any service, product or procedure:

1. that is unsafe, ineffective, or experimental or investigational.
2. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider's documentation shows that the requested service is medically necessary "to correct or ameliorate a defect, physical or mental illness, or a condition" [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary's health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

#### **EPSDT and Prior Approval Requirements**

1. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does NOT eliminate the requirement for prior approval.
2. **IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the *NCTracks Provider Claims and Billing Assistance Guide*, and on the EPSDT provider page. The Web addresses are specified below:

*NCTracks Provider Claims and Billing Assistance Guide:*

<https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html>

*EPSDT provider page:* <https://medicaid.ncdhhs.gov/>

#### *Provider(s) Eligible to Bill for the Procedure, Product, or Service*

To be eligible to bill for the procedure, product, or service related to this policy, the provider(s) shall:

- a. meet Medicaid qualifications for participation;
- b. have a current and signed Department of Health and Human Services (DHHS) Provider Administrative Participation Agreement; and
- c. bill only for procedures, products, and services that are within the scope of their clinical practice, as defined by the appropriate licensing entity.

#### *Compliance*

Provider(s) shall comply with the following in effect at the time the service is rendered:

- a. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and
- b. All NC Medicaid's clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).

## CLINICAL POLICY WNC.CP.125

### FECAL INCONTINENCE TREATMENTS

#### *Claims-Related Information*

Provider(s) shall comply with the NC Tracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, NC Medicaid's clinical coverage policies and any other relevant documents for specific coverage and reimbursement for Medicaid:

- a. Claim Type - as applicable to the service provided:
  - Professional (CMS-1500/837P transaction)
  - Institutional (UB-04/837I transaction)Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines.
- b. International Classification of Diseases and Related Health Problems, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS) - Provider(s) shall report the ICD-10-CM and Procedural Coding System (PCS) to the highest level of specificity that supports medical necessity. Provider(s) shall use the current ICD-10 edition and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for code description, as it is no longer documented in the policy.
- c. Code(s) - Provider(s) shall report the most specific billing code that accurately and completely describes the procedure, product or service provided. Provider(s) shall use the Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and UB-04 Data Specifications Manual (for a complete listing of valid revenue codes) and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for the code description, as it is no longer documented in the policy. If no such specific CPT or HCPCS code exists, then the provider(s) shall report the procedure, product or service using the appropriate unlisted procedure or service code.

#### *Unlisted Procedure or Service*

CPT: The provider(s) shall refer to and comply with the Instructions for Use of the CPT Codebook, Unlisted Procedure or Service, and Special Report as documented in the current CPT in effect at the time of service.

HCPCS: The provider(s) shall refer to and comply with the Instructions For Use of HCPCS National Level II codes, Unlisted Procedure or Service and Special Report as documented in the current HCPCS edition in effect at the time of service

- d. Modifiers - Providers shall follow applicable modifier guidelines.
- e. Billing Units - Provider(s) shall report the appropriate code(s) used which determines the billing unit(s).
- f. Co-payments -  
For Medicaid refer to Medicaid State Plan:  
<https://medicaid.ncdhhs.gov/meetingsnotices/medicaid-state-plan-public-notices>
- g. Reimbursement - Provider(s) shall bill their usual and customary charges. For a schedule of rates, refer to: <https://medicaid.ncdhhs.gov/>.

#### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted

## **CLINICAL POLICY WNC.CP.125**

### **FECAL INCONTINENCE TREATMENTS**

standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**CLINICAL POLICY WNC.CP.125**  
**FECAL INCONTINENCE TREATMENTS**



©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.

DRAFT